# A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients

Study · id `cardio:ct-nct02616666` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02616666](<https://clinicaltrials.gov/study/NCT02616666>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02616666

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 632 participants.

## Technical summary

Registry record NCT02616666. Randomized; no masking; primary purpose treatment. Start 2016-08-25 (actual); primary completion 2025-12-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 632 participants (enrolled count; ClinicalTrials.gov record NCT02616666, source copy `cardio:ctgov-nct02616666-2026-02-20`, retrieved 2026-10-26)
- Started: 2016-08-25 (actual) (ClinicalTrials.gov record NCT02616666, source copy `cardio:ctgov-nct02616666-2026-02-20`, retrieved 2026-10-26)
- Primary completion: 2025-12-12 (actual) (ClinicalTrials.gov record NCT02616666, source copy `cardio:ctgov-nct02616666-2026-02-20`, retrieved 2026-10-26)
- Completion: 2025-12-12 (actual) (ClinicalTrials.gov record NCT02616666, source copy `cardio:ctgov-nct02616666-2026-02-20`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT02616666, source copy `cardio:ctgov-nct02616666-2026-02-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02616666-2026-02-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients
- Acronym: DECIDE
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Standard of Care
- Lead sponsor: University of Liverpool
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY
- Collaborator: Clinical Practice Research Datalink
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: University of Liverpool (`cardio:org-university-of-liverpool`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: caca5c6ba3ed5e83b572a9e615e4f64f888d873e1bc710f97159b956219384f5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
